June 15, 2026
Parkinson’s Disease Statistics Everyone Should Know
Quick answer: Parkinson’s disease affects over 10 million people worldwide and is the second-most common neurodegenerative disease. Nearly 90,000 Americans are diagnosed each year, with men 1.5 times more likely to develop it than women. U.S. treatment costs approach $82.2 billion annually.
Parkinson’s disease (PD) touches millions of lives, yet many people don’t realize how widespread — or how costly — it has become. Understanding the numbers behind this condition helps patients, caregivers, and researchers grasp its true scope.
Below, Gladiator Therapeutics shares the key Parkinson’s disease statistics everyone should know, along with how innovative far-infrared therapy may support those living with the disease.
What Are the Demographics and Prevalence of Parkinson’s Disease?
Parkinson’s disease is rising fast as the global population ages. These statistics about Parkinson’s disease reveal just how many people it affects:
- U.S. burden: An estimated 1.1 to 1.5 million people in the United States currently live with Parkinson’s, a number projected to exceed 1.2 million by 2030 (Parkinson’s Foundation).
- Global impact: Worldwide, over 11 million individuals live with the disease, and cases have more than doubled over the last two decades.
- New diagnoses: Nearly 90,000 Americans are diagnosed with PD every year.
- Age: The risk of Parkinson’s increases with age, but about 4% of people are diagnosed before the age of 50.
- Gender: Men are roughly 1.5 times more likely to develop Parkinson’s disease than women.
What Do the Biology and Symptoms of Parkinson’s Disease Tell Us?
The biology behind Parkinson’s explains why the disease is often hard to catch early:
- Motor symptoms: The classic motor symptoms of PD — such as tremors, stiffness, and slowness — only become evident after 60% to 80% of the brain’s dopamine-producing neurons have been lost or impaired. This means significant damage often happens before a diagnosis.
- Genetics: Genetics account for only about 10% to 15% of all Parkinson’s cases. Researchers believe a combination of genetic, environmental, and lifestyle factors causes the disease.
What Are the Economic and Health Impacts of Parkinson’s Disease?
The financial and health toll of Parkinson’s is significant for individuals and society alike:
- Cost: The annual healthcare cost for treating Parkinson’s disease in the U.S. is nearing $82.2 billion.
- Mortality: While PD itself is not considered directly fatal, complications from the disease are a major leading cause of death, often related to falls or swallowing difficulties.
Tracking these numbers matters. Reliable data helps researchers develop better treatments and guides where research resources should go.
How Is Gladiator Therapeutics Supporting Parkinson’s Disease Management?
Gladiator Therapeutics is committed to innovation in medical devices that align closely with the needs of Parkinson’s patients. This commitment includes:
- Enhancing comfort and mobility with innovative products
- Collaborating with world-renowned neurologists
- Participating in clinical trials
- Providing patient education and support resources
What Is the Potential of Gladiator Therapeutics Devices for Parkinson’s Disease?
Gladiator Therapeutics’ SemiCera® Technology may offer a non-invasive, supportive treatment that addresses both motor and non-motor symptoms by improving underlying cellular functions. Its potential benefits include:
- Stimulation of healing
- Prevention of tissue necrosis
- Increases in mitochondrial function
- Improvement in blood flow and tissue oxygenation
- Anti-inflammatory effects
For Parkinson’s specifically, the SemiCera® Technology holds promise by:
- Improving mitochondrial function, which is reversible and crucial in PD pathogenesis
- Reducing neuroinflammation, thereby possibly slowing disease progression
- Enhancing overall cellular health and function, which could ease some of the motor and non-motor symptoms of PD
Explore Far Infrared Therapy for Parkinson’s Symptoms
If you live with Parkinson’s disease, love someone who does, or worry about developing it, you have options worth exploring. Gladiator Therapeutics’ far infrared therapy products are designed to support better management of Parkinson’s symptoms and improve quality of life. Reach out today to learn how these non-invasive devices could help you or your loved ones.
Parkinson’s disease affects millions and carries a steep human and economic cost. As cases continue to rise with an aging population, awareness and innovation become more important than ever. The statistics above paint a clear picture: better treatments and supportive therapies are urgently needed. Gladiator Therapeutics is proud to contribute to that effort with research-backed, non-invasive solutions.
Frequently Asked Questions
How Many People Have Parkinson’s Disease?
Over 10 million people worldwide live with Parkinson’s disease, including an estimated 1.1 to 1.5 million in the United States. Global cases have more than doubled over the past two decades.
Who Is Most at Risk of Developing Parkinson’s Disease?
Risk increases with age, and men are roughly 1.5 times more likely than women to develop Parkinson’s. However, about 4% of people are diagnosed before age 50, showing that younger adults can be affected too.
Is Parkinson’s Disease Genetic?
Genetics account for only about 10% to 15% of Parkinson’s cases. Most cases result from a combination of genetic, environmental, and lifestyle factors.
How Much Does Parkinson’s Disease Cost to Treat?
The annual healthcare cost for treating Parkinson’s disease in the U.S. is nearing $82.2 billion, covering medical care, lost income, and related expenses.
Can Far Infrared Therapy Help With Parkinson’s Symptoms?
Gladiator Therapeutics’ SemiCera® Technology may serve as a non-invasive adjunct therapy. It aims to improve mitochondrial function, reduce neuroinflammation, and support cellular health, which could help manage both motor and non-motor symptoms.